Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

18 Biggest Mid-Day Losers For Tuesday

Share:
  • EnteroMedics Inc (NASDAQ: ETRM) shares dropped 24 percent to $4.64 after the company reported its earnings for the three-month period ending March 31, 2017, and an overview of its recent commercialization and corporate achievements. During the quarter, the company reported sales of $40,000 with gross profits totaling $11,000. Net loss for the quarter totaled $7.4 million while the company ended the period with cash, cash equivalents and short-term investments of $18.7 million.
  • Bovie Medical Corporation (NYSE: BVX) shares dipped 23.8 percent to $2.02. Bovie Medical reported a Q1 loss of $0.06 per share on sales of $8.4 million.
  • Mirna Therapeutics Inc (NASDAQ: MIRN) shares tumbled 20.2 percent to $1.62. Synlogic and Mirna Therapeutics agreed to merge in an all-stock deal.
  • Pernix Therapeutics Holdings Inc (NASDAQ: PTX) fell 18.2 percent to $4.69. Pernix Therapeutics reported a Q1 loss of $2.94 per share on revenue of $29.742 million.
  • ImmunoCellular Therapeutics Ltd (NYSE: IMUC) shares declined 16 percent to $1.31. ImmunoCellular Therapeutics reported a Q1 loss of $1.64 per share.
  • Xenetic Biosciences Inc (NASDAQ: XBIO) fell 15.6 percent to $2.70 as the company posted a wider-than-expected quarterly loss.
  • Virtusa Corporation (NASDAQ: VRTU) declined 14.8 percent to $27.61 on downbeat Q4 results.
  • VOXX International Corp (NASDAQ: VOXX) shares dipped 13.4 percent to $6.15 after the company posted weak quarterly results.
  • TearLab Corp (NASDAQ: TEAR) declined 11.5 percent to $2.30 after the company posted disappointing quarterly results.
  • Akers Biosciences Inc (NASDAQ: AKER) dropped 11.4 percent to $1.55. Akers Biosciences posted Q1 net loss attributable to shareholders of $1,349,270, and revenue $667,250.
  • Fate Therapeutics Inc (NASDAQ: FATE) shares fell 11.2 percent to $3.65 as the company posted a bigger-than-expected Q1 loss.
  • Dicks Sporting Goods Inc (NYSE: DKS) shares declined 10.8 percent to $42.47. Dicks posted in-line quarterly earnings but same-store sales missed estimates. UBS downgraded Dick's from Buy to Hold.
  • Viewray Inc (NASDAQ: VRAY) dropped 10 percent to $6.30. ViewRay reported a Q1 loss of $28 million on sales of $1.2 million.
  • Forterra Inc (NASDAQ: FRTA) tumbled 9.6 percent to $13.50. RBC Capital downgraded Forterra from Outperform to Sector Perform, while SunTrust Robinson Humphrey downgraded the stock from Buy to Hold.
  • Capricor Therapeutics Inc (NASDAQ: CAPR) fell 9.3 percent to $1.08 on wider-than-expected quarterly loss.
  • Staples, Inc. (NASDAQ: SPLS) declined 4.8 percent to $8.87. Staples posted upbeat profit for its first quarter, but sales missed expectations.
  • Stratasys, Ltd. (NASDAQ: SSYS) declined 3 percent to $29.04. Stratasys posted in-line quarterly earnings.
  • M.D.C. Holdings, Inc. (NYSE: MDC) fell 3 percent to $34.56. Wells Fargo downgraded M.D.C. from Market Perform to Underperform.

Posted-In: Mid-Day LosersNews Movers & Shakers Intraday Update Markets Analyst Ratings

 

Related Articles (BVX + AKER)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
YUMMaintains105.0
MARMaintains135.0
DELLMaintains85.0
EOLSInitiates Coverage On6.0
DXCMaintains70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

The President And The Russians: Are There Any Adults Capable Of 'Restraining Trump's Impulses?'

Chef's Warehouse, Performance Food Group: 2 Food Names Analysts Find Appetizing